[go: up one dir, main page]

HK1202053A1 - 肝臟狀況的治療 - Google Patents

肝臟狀況的治療

Info

Publication number
HK1202053A1
HK1202053A1 HK15102509.3A HK15102509A HK1202053A1 HK 1202053 A1 HK1202053 A1 HK 1202053A1 HK 15102509 A HK15102509 A HK 15102509A HK 1202053 A1 HK1202053 A1 HK 1202053A1
Authority
HK
Hong Kong
Prior art keywords
treatment
liver conditions
liver
conditions
Prior art date
Application number
HK15102509.3A
Other languages
English (en)
Inventor
Pnina Fishman
Shira Cohen
Sara Bar-Yehuda
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of HK1202053A1 publication Critical patent/HK1202053A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15102509.3A 2012-01-23 2015-03-11 肝臟狀況的治療 HK1202053A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589430P 2012-01-23 2012-01-23
US201361752118P 2013-01-14 2013-01-14
PCT/IL2013/050064 WO2013111132A1 (en) 2012-01-23 2013-01-23 Treatment of liver conditions

Publications (1)

Publication Number Publication Date
HK1202053A1 true HK1202053A1 (zh) 2015-09-18

Family

ID=47749911

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102509.3A HK1202053A1 (zh) 2012-01-23 2015-03-11 肝臟狀況的治療

Country Status (6)

Country Link
US (1) US20150018299A1 (zh)
EP (1) EP2806878A1 (zh)
JP (1) JP2015504088A (zh)
CN (1) CN104159589A (zh)
HK (1) HK1202053A1 (zh)
WO (1) WO2013111132A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL242723B (en) * 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
KR101881441B1 (ko) * 2017-01-20 2018-07-24 서울대학교산학협력단 다중 약리단 특성에 기반한 비정상적 아디포넥틴 관련 질환 치료용 조성물
CN109666053A (zh) * 2017-10-16 2019-04-23 张家口华健致远生物科技有限公司 一种a3腺苷受体激动剂及其用途
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina Adenosine a3 receptor ligand for use in lowering adipocyte levels
IL272078A (en) 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in therapy
JP2023099919A (ja) * 2022-01-04 2023-07-14 キャン－ファイト バイオファーマ リミテッド 進行した転移性がんの治療

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824483A (en) * 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US6833361B2 (en) * 1998-05-26 2004-12-21 Ribapharm, Inc. Nucleosides having bicyclic sugar moiety
SK17432000A3 (sk) * 1998-05-26 2001-07-10 Icn Pharmaceuticals, Inc. Zlúčenina, ktorá zahŕňa nukleozid s 2',4'-mostíkom a oligonukleotid z nej odvodený
US6790839B2 (en) * 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
BR0206492A (pt) * 2001-01-16 2004-02-10 Can Fite Biopharma Ltd Composição farmacêutica para inibir a replicação de um vìrus dentro de células, uso de pelo menos um agonista receptor de adenosina a3, e, métodos para inibir a replicação de um vìrus em células
US7141553B2 (en) * 2002-11-19 2006-11-28 Can-Fite Biopharma Ltd. Israel A3AR agonists for the treatment of inflammatory arthritis
ES2287804T3 (es) * 2003-12-29 2007-12-16 Can-Fite Biopharma Ltd. Metodo para el tratamiento de esclerosis multiples.
WO2007043054A1 (en) 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
WO2009050707A1 (en) * 2007-10-15 2009-04-23 Can-Fite Biopharma Ltd. Method for inducing hepatocyte proliferation and uses thereof

Also Published As

Publication number Publication date
CN104159589A (zh) 2014-11-19
JP2015504088A (ja) 2015-02-05
EP2806878A1 (en) 2014-12-03
US20150018299A1 (en) 2015-01-15
WO2013111132A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
HK1207574A1 (zh) 骨髓抑制的治療
HK1205759A1 (zh) 生物質量的處理
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
ZA201406082B (en) Use of ccr3-inhibitors
HK1214128A1 (zh) 癌症的治療
HK1204956A1 (zh) 癌症治療
IL236312A0 (en) Preparation of 18f-flucyclobin
HK1202053A1 (zh) 肝臟狀況的治療
GB201217892D0 (en) Treatment of cancer
GB201309274D0 (en) Treatment Of Fuel
IL238592A0 (en) Methods for treating liver diseases
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
ZA201501038B (en) Treatment of wax
GB201207907D0 (en) Treatment of depression
GB201217890D0 (en) Treatment of cancer
IL233740A0 (en) Treatment of liver diseases
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201212717D0 (en) Treatment of musculoskeletal conditions
GB201206325D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment